array(3) { ["company_details"]=> array(13) { ["name"]=> string(28) "Bristol-Myers Squibb Company" ["slug"]=> string(37) "81631-us-bristol-myers-squibb-company" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/7b41874f-2658-484b-890c-9b9bd5a41f13" ["description"]=> string(1400) "At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html" ["address_street"]=> string(19) "430 E 29TH St FL 14" ["address_place"]=> string(8) "New York" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1887-02-28" ["website_domain"]=> string(7) "bms.com" ["website_url"]=> string(19) "https://www.bms.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(1200) ["article_count"]=> int(2495) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(61) "Bristol Hits Medicare With Fresh Suit Over Price Negotiations" ["snippet_en"]=> string(199) "Bristol-Myers Squibb Co. is stepping into the fight to block Medicare’s new authority to negotiate the prices of certain drugs, filing its own federal lawsuit against the federal government Friday." ["url"]=> string(115) "https://news.bloomberglaw.com/health-law-and-business/bristol-hits-medicare-with-fresh-suit-over-price-negotiations" ["image_url"]=> string(78) "https://images.businessradar.com/articles/6f90e5f6-7c51-468c-8dda-edfc14d5f35a" ["source"]=> string(16) "bloomberglaw.com" ["publication_date"]=> string(10) "2023-06-16" ["categories"]=> array(6) { [0]=> string(24) "Government Interventions" [1]=> string(21) "Competitive Behaviour" [2]=> string(10) "Litigation" [3]=> string(46) "Management of Legal and Regulatory Environment" [4]=> string(19) "Government Policies" [5]=> string(5) "Legal" } } [1]=> array(7) { ["title_en"]=> string(63) "Bristol-Myers, Cancer Institute Settle Patent Ownership Lawsuit" ["snippet_en"]=> string(274) "The Dana-Farber Cancer Institute Inc. and drugmakers Bristol-Myers Squibb Co. and Ono Pharmaceutical Co. have reached a truce, settling a four-year legal feud over whether the pharma firms cut the institute out of ownership rights for lucrative cancer immunotherapy patents." ["url"]=> string(99) "https://news.bloomberglaw.com/ip-law/bristol-myers-cancer-institute-settle-patent-ownership-lawsuit" ["image_url"]=> string(78) "https://images.businessradar.com/articles/9d9ea64c-009b-4bf7-b772-032bb8d35b77" ["source"]=> string(16) "bloomberglaw.com" ["publication_date"]=> string(10) "2023-04-10" ["categories"]=> array(2) { [0]=> string(10) "Litigation" [1]=> string(5) "Legal" } } [2]=> array(7) { ["title_en"]=> string(86) "Bristol-Myers Squibb Forecasted to Post Q1 2023 Earnings of $2.02 Per Share (NYSE:BMY)" ["snippet_en"]=> string(210) "Bristol-Myers Squibb (NYSE:BMY – Get Rating) – Jefferies Financial Group issued their Q1 2023 earnings per share (EPS) estimates for shares of Bristol-Myers Squibb in a report released on Monday, March 6th." ["url"]=> string(127) "https://www.defenseworld.net/2023/03/08/bristol-myers-squibb-forecasted-to-post-q1-2023-earnings-of-2-02-per-share-nysebmy.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/3d7aa7a0-a0c9-4601-94d3-cb506f21e3a5" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-03-08" ["categories"]=> array(5) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(24) "Stock Research & Ratings" [2]=> string(12) "Stock Market" [3]=> string(10) "Litigation" [4]=> string(14) "Issuing Shares" } } [3]=> array(7) { ["title_en"]=> string(68) "U.S. Supreme Court Won't Decide Scope Of Wage-and-hour Class Actions" ["snippet_en"]=> string(222) "The U.S. Supreme Court on Monday again declined to settle a split among appeals courts over whether federal wage law allows workers to bring nationwide class action-style lawsuits, turning away a case involving FedEx Corp." ["url"]=> string(90) "https://www.ibtimes.com/us-supreme-court-wont-decide-scope-wage-hour-class-actions-3674204" ["image_url"]=> string(78) "https://images.businessradar.com/articles/301426fe-8ba2-4b1a-a17a-76090af8b973" ["source"]=> string(11) "ibtimes.com" ["publication_date"]=> string(10) "2023-03-06" ["categories"]=> array(7) { [0]=> string(8) "Verdicts" [1]=> string(10) "Litigation" [2]=> string(15) "Business Ethics" [3]=> string(15) "Labor Practices" [4]=> string(46) "Management of Legal and Regulatory Environment" [5]=> string(5) "Legal" [6]=> string(26) "Product Quality and safety" } } [4]=> array(7) { ["title_en"]=> string(120) "Personal Jurisdiction of Opt-In Plaintiffs Under the FLSA: Will the Supreme Court Resolve the Circuit Split this Summer?" ["snippet_en"]=> string(181) "Following the U.S. Supreme Court’s landmark opinion in Bristol-Myers Squibb Co. v. Superior Court of California, 137 S. Ct. 1773 (2017), a question arising under the Fair Labor St" ["url"]=> string(119) "https://www.natlawreview.com/article/personal-jurisdiction-opt-plaintiffs-under-flsa-will-supreme-court-resolve-circuit" ["image_url"]=> string(78) "https://images.businessradar.com/articles/53d51da6-5c96-485c-bec8-9b7af86b2c9d" ["source"]=> string(16) "natlawreview.com" ["publication_date"]=> string(10) "2023-03-03" ["categories"]=> array(5) { [0]=> string(8) "Verdicts" [1]=> string(10) "Litigation" [2]=> string(5) "Legal" [3]=> string(5) "Event" [4]=> string(11) "Regulations" } } [5]=> array(7) { ["title_en"]=> string(78) "Gamco Investors INC. ET AL Sells 706 Shares of Bristol-Myers Squibb (NYSE:BMY)" ["snippet_en"]=> string(220) "Gamco Investors INC. ET AL trimmed its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 0.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission." ["url"]=> string(119) "https://www.defenseworld.net/2023/02/27/gamco-investors-inc-et-al-sells-706-shares-of-bristol-myers-squibb-nysebmy.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/d2467840-b681-4e5b-9337-5650dc88bdd3" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-02-27" ["categories"]=> array(3) { [0]=> string(10) "Litigation" [1]=> string(14) "Issuing Shares" [2]=> string(12) "Stock Market" } } [6]=> array(7) { ["title_en"]=> string(51) "Bristol-Myers Squibb (NYSE:BMY) PT Raised to $62.00" ["snippet_en"]=> string(295) "Bristol-Myers Squibb (NYSE:BMY – Get Rating) had its price objective boosted by stock analysts at Morgan Stanley from $60.00 to $62.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has an “underweight” rating on the biopharmaceutical company’s stock." ["url"]=> string(91) "http://www.defenseworld.net/2023/02/05/bristol-myers-squibb-nysebmy-pt-raised-to-62-00.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/193e69bb-1602-46d9-9867-838f1646803b" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-02-05" ["categories"]=> array(3) { [0]=> string(10) "Litigation" [1]=> string(12) "Stock Market" [2]=> string(21) "Competitive Behaviour" } } [7]=> array(7) { ["title_en"]=> string(84) "FY2022 Earnings Forecast for Bristol-Myers Squibb Issued By William Blair (NYSE:BMY)" ["snippet_en"]=> string(221) "Bristol-Myers Squibb (NYSE:BMY – Get Rating) – Research analysts at William Blair dropped their FY2022 earnings per share estimates for shares of Bristol-Myers Squibb in a research note issued on Monday, January 23rd." ["url"]=> string(126) "https://www.defenseworld.net/2023/01/27/fy2022-earnings-forecast-for-bristol-myers-squibb-issued-by-william-blair-nysebmy.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/f81f8dc1-cbf7-429c-8482-df5610f75e91" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-01-27" ["categories"]=> array(5) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(12) "Stock Market" [2]=> string(10) "Litigation" [3]=> string(14) "Issuing Shares" [4]=> string(5) "Legal" } } [8]=> array(7) { ["title_en"]=> string(61) "Bristol-Myers Sues AstraZeneca for Profits Lost to Imjudo (1)" ["snippet_en"]=> string(264) "Bristol-Myers Squibb Co. alleges that AstraZeneca Plc’s new cancer immunotherapy Imjudo infringes two patents for Bristol’s Yervoy, an antibody that helps the immune system target and kill cancer cells and was the world’s first approved checkpoint inhibitor." ["url"]=> string(100) "https://news.bloomberglaw.com/ip-law/bristol-myers-sues-astrazeneca-for-profits-lost-to-imjudo-sales" ["image_url"]=> string(78) "https://images.businessradar.com/articles/f2a001ca-43ff-452b-8cb7-bf6b5ba37c26" ["source"]=> string(16) "bloomberglaw.com" ["publication_date"]=> string(10) "2023-01-24" ["categories"]=> array(3) { [0]=> string(10) "Litigation" [1]=> string(21) "Financial Performance" [2]=> string(5) "Legal" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(254) } [1]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(163) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(151) } [3]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(94) } [4]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(89) } [5]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(76) } [6]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(74) } [7]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(64) } [8]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(63) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(60) } [10]=> array(2) { ["name"]=> string(6) "Merger" ["count"]=> int(60) } [11]=> array(2) { ["name"]=> string(17) "Energy Management" ["count"]=> int(56) } [12]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(54) } [13]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(47) } [14]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(47) } [15]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(45) } [16]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(45) } [17]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(42) } [18]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(39) } [19]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(35) } [20]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(35) } [21]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(33) } [22]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(32) } [23]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(28) } [24]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(27) } [25]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(26) } [26]=> array(2) { ["name"]=> string(12) "Going Public" ["count"]=> int(24) } [27]=> array(2) { ["name"]=> string(10) "Divestment" ["count"]=> int(22) } [28]=> array(2) { ["name"]=> string(9) "Valuation" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(15) "Blogs & Columns" ["count"]=> int(21) } } } 81631-us-bristol-myers-squibb-company